The neurotechnology start-up has raised £850,000 in funding, led by SFC Capital to develop its medical-grade wearable.
MindSpire, a neurotechnology start-up based at the London Institute for Healthcare Engineering (LIHE), has raised £850,000 in its first pre-seed funding to launch SONA, its medical-grade earpiece that delivers personalised, real-time stress relief using adaptive AI and precision vagus nerve stimulation.
The round was led by early-stage investment firm SFC Capital, with participation from venture capital fund SyndicateRoom and non-dilutive innovation funding secured via Innovate UK’s Investor Partnership Programme.
The investment will enable MindSpire to complete the development and launch of SONA.
Chronic stress
MindSpire was founded to address the impact of chronic stress on health. The start-up’s AI-driven platform combines vagus nerve stimulation with real-time personalisation to enhance cognitive function and emotional regulation, enabling users to optimise their mental states and improve focus, learning and resilience.
“Our goal is to create a solution that performs just as well for executives managing stress and recovery as it does for individuals rebuilding from chronic conditions. It reflects our commitment to making nervous system care accessible, especially for those who need it most,” said Jane Ollis, founder and chief executive of MindSpire.
MindSpire said that it is now actively building strategic partnerships with health platforms and innovators in stress, sleep, longevity and performance. The team is also speaking with investors ahead of its next funding round.
